Telix Pharmaceuticals Investors May be Eligible for Compensation Through Securities Class Action Investigation

Rosen Law Firm is investigating potential securities claims against Telix Pharmaceuticals Ltd. (NASDAQ: TLX) following allegations of materially misleading business information. Investors who purchased Telix securities may be entitled to compensation without payment of any out-of-pocket fees or costs through a contingency fee arrangement. To join the prospective class action, visit https://rosenlegal.com/submit-form/?case_id=43778 or call Phillip Kim, Esq. at 866-767-3653.